Medeon Biodesign Completes First Studies for XPro Device

Taipei, Taiwan-based Medeon Biodesign completed first-in-man studies for its XPro suture-mediated vascular closure device.

The devices were deployed in 10 patients undergoing interventional catheterization procedures using 14F-18F sheaths, and achieved immediate or rapid hemostasis at the puncture sites.

“Currently, there are very limited device options indicated for large bore access sites and many improvement opportunities for currently marketed devices,” says Dr. Yue-Teh Jang, CEO of Medeon Biodesign. “We believe that the XProTM suture-mediated vascular closure device can provide a new choice for interventionalists and patients worldwide.” — Michael Cipriano